Off-target APOBEC activity promotes tumorigenesis by causing oncogenic driver mutations such as PIK3CA E542K or PIK3CA E545K (14) and can contribute to therapeutic resistance to tamoxifen in estrogen receptor-positive breast cancer cells (15). The gene discussed is PIK3CA; the disease is breast carcinoma.